repetitive treatment of issues. Thus, without preempting any 
regulatory authority, the RAC would become a focal point for 
efficiently addressing rDNA issues important to both science and 
commercial development. Under such a reasonable regime, 
industry's commitment to full compliance with RAC guidance would 
be expected to continue and be strengthened. 
To move toward successful implementation of this role, 
we offer two specific suggestions. First, both the Large Scale 
Review Working Group and the RAC itself would benefit by being 
kept better informed on what is taking place in industry. We 
therefore suggest that an industry representative be placed on 
each body - without voting power but with responsibility to 
insure that industrial approaches and perspectives are taken into 
account on decisions affecting such interests. If we were 
requested to do so, IBA would be pleased to designate an expert 
with actual large scale rDNA experience to serve in this role. 
Secondly, we believe that dialogue between the IBA and 
the Large Scale Review Working Group should continue periodically 
on a regular basis. We have freely expressed some of our 
committee's views and concerns to you today. We look forward to 
hearing whatever questions you may have. In light of your 
responsibility to advise the RAC on scale-up matters, we are 
confident that a regular channel of communication can be 
established which will promote understanding and respect for our 
various points of view, which will sharpen Issues that should be 
constructively addressed and which will minimize undue strains on 
the NIH and industrial community as we pursue compatible goals. 
- 9 - 
[ 538 ] 
